Full year 2025 net cash used in operating activities is expected to be in the range of $120 million to $145 million. The cash position at February 27, 2025 is expected to be sufficient to fund operating expenses and capital expenditure requirements at least through the planned 26-week data read-out from the COMP006 study, which is expected in the second half of 2026.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPS:
- Positive Outlook for COMPASS Pathways Amid Psychedelic Acceptance and Strategic Investment Opportunity
- Compass Pathways initiated with a Buy at Stifel
- Psychedelic: Exclusive talk with biotech company Enveric Biosciences
- Compass Pathways price target lowered to $45 from $60 at H.C. Wainwright
- Psychedelic: Relmada acquires neurosteroid from Asarina